Systemic lupus erythematosus is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens and immune-complex formation.
It can be diagnosed with a single organ involvement such as lupus nephritis.
It is predominantly diagnosed in females of childbearing age.
Clinical presentation varies in different patients and the disease activity varies over time in a single patient. Majority of patients have arthralgia of the hand.
Belimumab treatment for systemic lupus erythematosus may induce low disease activity and clinical remission in patients with limited or no organ damage, as well as with positive antidouble stranded DNA titres, according to a study.
Treatment with cyclosporine as maintenance therapy for lupus nephritis appears to lead to faster remission of proteinuria compared with mycophenolate mofetil (MMF) or azathioprine (AZA), although all three drugs are effective in maintaining renal remission in the long run, suggests a study presented at EULAR 2019.
Using belimumab in the treatment of systemic lupus erythematosus leads to a slower organ damage progression, as well as a smaller magnitude of progression, compared with standard of care alone, according to a study.
An association exists between poor/intermediate preconceptional cardiovascular (CV) health and pregnancy outcomes of preterm birth and small for gestational age (SGA) infants among women with systemic lupus erythematosus (SLE), suggests a recent study.
Psychosis as a manifestation of neuropsychiatric (NP) systemic lupus erythematosus occurs rarely, taking place after SLE onset and negatively affecting health status, a study reports. Short- and long-term outlook appears to be good for most patients, although vigilant follow-up is needed.
The addition of ustekinumab to standard-of-care (SOC) treatment resulted in improved outcomes in adults with systemic lupus erythematosus (SLE) whose disease activity persisted despite standard treatment, according to a phase II trial.
Patients with systemic lupus erythematosus on hydroxychloroquine fare better, having lower mortality rates compared with those not using the drug, a study has shown. This survival benefit is further enhanced by treatment adherence.
Hydroxychloroquine (HCQ) inhibits the differentiation of Th17 cells and production of interleukin 17 (IL-17) both in vitro and in patients with systemic lupus erythematosus (SLE), a recent study has shown.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.